| 摘要 |
A method of manufacture of a medicament for the inhibition of phospholipase A2 in the control of inflammation, wherein delta-6,9,12,15-octadecatetraenoic acid (stearidonic acid) and/or delta-8,11,14,17-eicosatetraenoic acid is presented as said medicament alone or in a pharmaceutically acceptable diluent or carrier.
|
